From the Editor
  • Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.
  • The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024.
  • Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide.
  • Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
Wealth History
HOVER TO REVEAL NET WORTH BY YEAR
Personal Stats
Age
61
Source of Wealth
Pharmaceuticals, Self Made
Residence
Chengdu, China
Citizenship
China
Did you know
Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.
Related People & Companies
Zhong Huijuan
Zhong Huijuan
Related by origin of wealth: Pharmaceuticals
View Profile
Sichuan Biokin Pharmaceutical
Sichuan Biokin Pharmaceutical
Holds stake in Sichuan Biokin Pharmaceutical
View Profile
China
China
Citizen of China
View Profile
Dilip Shanghvi & family
Dilip Shanghvi & family
Related by origin of wealth: Pharmaceuticals
View Profile
Setiawan family
Setiawan family
Related by origin of wealth: Pharmaceuticals
View Profile
Pankaj Patel
Pankaj Patel
Related by origin of wealth: Pharmaceuticals
View Profile

More on Forbes

Sep 23, 2025

Raising Cane's: The Origin Story Of This $22 Billion Empire

In his early 20s, Todd Graves, dismissed by banks as a naive kid with a bad idea, turned his fanatic vision for chicken fingers into Raising Cane's. Now, Graves is worth $22 billion, and with over 900 locations, Raising Cane’s is one of America's fastest-growing fast-food chains.